Randomized Phase II of TARCEVA (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Erlotinib (Primary) ; Carmustine; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 16 Feb 2009 Status changed from active, no longer recruiting to completed.
- 09 Feb 2009 Primary endpoint 'Progression free survival rate' has not been met.
- 23 Sep 2007 Results were presented at ECCO 2007.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History